Despite the results of these promising large-scale clinical trials, a recently published analysis suggests that SGLT2 inhibitors remain underutilized in patients with CKD, especially in patients without diabetes mellitus (DM) (Zhuo et al., 2022). This evidence concerns the gene SLC5A2 and chronic kidney disease.